CanPathPro: Generation of the CanPath prototype - a platform for predictive cancer pathway modeling

Recent developments in omics technologies demand implementation of systems biology approaches to facilitate analysis and interpretation of the generated complex datasets. This is essential for biotechnological as well as preclinical and clinical applications. In comparison to previous approaches, most cancer relevant studies are confined to pattern recognition or at best modelling of single pathways, rather than the complex pathways and cross-talk determining cancer progression and drug response. Systematic tools that evaluate and validate personalised medicine approaches on a preclinical level are missing; an important prerequisite for translation into clinical practice.

The overall objective of CanPathPro is to build and validate a new biotechnological application: a combined experimental and systems biology platform, which will be utilized in testing cancer signaling hypotheses in biomedical research and life sciences. Thus, the project will focus on developing a bioinformatic concept and the associated computational tools required for the translation of highly complex and heterogeneous omics data into predictive modelling of cancer signalling. The approach will utilise existing data and databases relevant to cancer signalling as well as CanPathPro-generated mouse omics data obtained from mouse cancer models, for practical testing and validation of the system. These data will be integrated by an existing modelling computational platform, to identify signalling networks critical for breast and lung cancer development.

In the project, Simula will play a central role in development efficient numerical algorithms for accurate simulation of highly-complex genome-scale models. Simula will also lead the development of novel methods for visualization of large heterogenous datasets. Furthermore, we will work on data-driven dynamical modelling for model-based integration of different datasets, critical assessment of available information, and comparison of competing biological hypotheses.

The developed system tools will be made available to researchers, SMEs and industry for practical applications. Following this project, a commercial platform for interpretation and analysis of complex omics data and for deriving and testing new hypotheses will be set up by the Consortium.

Overall, CanPathPro combines, in an absolutely novel approach, classic cancer research methodology with omics and systems biology tools. Hence the project will serve as a source of new biotechnological applications, in animal-based cancer research, and their utilisation in health-relevant applications.


  1. Alacris Theranostics GmbH, Germany (coordinator)
  2. Institut Clinique de la Souris, France
  3. Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, Netherlands
  4. Leibniz Institute for Age Research - Fritz Lipmann Institute, Germany
  5. Helmholtz Zentrum München, Germany
  6. Agencia Estatal Consejo Superior de Investigaciones Cientificas, Spain
  7. Biognosys AG, Switzerland
  8. Simula Research Laboratory AS, Norway
  9. Finovatis, France


  • H2020

Find publication


Cardiac Modeling


01.03.2016 - 01.02.2021